Home › Obesity › NCT05746039
Feasibility of Semaglutide in Advanced Lung Disease
Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension * Age \> 18 * BMI \> 30 kg/m2 * Requires supplemental oxygen on exertion * Stable treatment regimen X 90 days * Use of disease-modifying therapy Exclusion Criteria: * Diabetes * Pregnant or Breastfeeding * Recent weight loss * Recent or chronic GI complaints * History of gastroparesis * History of scleroderma * Hospitalized at time of evaluation * Use of weight loss medication in last 90 days * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2) * Uncontrolled thyroid disease * History of acute/chronic pancreatitis * Prior suicide attempt * Suicidal ideation in last 90 days * Presence of a pacemaker or defibrillator
About the study
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.
The main question\[s\] it aims to answer are:
1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight?
Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
What is being tested
- Semaglutide Pen Injector (drug)
Sponsor: University of Pennsylvania · Participants: 8 · Started: Jan 29, 2024
Contact the study team
- Michaela R Anderson, MD · Phone: 215-662-3202
Official record on ClinicalTrials.gov — NCT05746039
Locations in the U.S.
| Pennsylvania | University of Pennsylvania Perelman School of Medicine, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.